Real-world Data in Patients With Breast Cancer Treated With Abemaciclib

Recruiting now

Conditions studied: Breast Cancer

In brief

The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.

Key facts

Study ID

NCT04985058

Run by

Hellenic Cooperative Oncology Group

People needed

108

Starts

2021-10-06

Expected to finish

2027-07-01

Last updated by the study team

2026-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed HR-positive, HER2-negative breast cancer
• Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
• 18 years or older
• Any menopausal status
• Treatment with abemaciclib in combination with endocrine therapy
• Any endocrine therapy
• At least two months of treatment with abemaciclib

Where it is running

• Hellenic Oncology Cooperative Group — Athens, Greece (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.